Podcasts about mpns

In this How I Treat series episode Blood Associate Editor, Dr. Jason Gotlib speaks with Drs. Aaron Gerds, Andreas Reiter, and Claire Harrison. The conversation focuses on the work and contributions of these authors to How I Treat Myeloproliferative Neoplasms, and exciting advances in the treatment and management of MPNs. See the full How I Treat series in volume 145 issue 16 of Blood.

This podcast episode covers highlights in myeloproliferative neoplasms (MPNs) from the 66th American Society of Hematology (ASH) Annual Meeting and... The post Post-ASH MPN highlights: key trial updates in MF, novel approaches being explored in R/R disease, & more! appeared first on VJHemOnc.

- Overview of Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET) - Staging & Diagnosing - Current Standard of Care & New Treatment Approaches - Understanding Common Symptoms - Working with Your Health Care Team to Manage Your Symptoms - Strategies to Reduce Potential Complications of MPNs - The Important Role of Clinical Trials - How Research Increases Your Treatment Options - Communicating with Your Health Care Team about Staging & Progression - Talking with Your Doctor about What Symptoms Should Prompt You or Your Caregiver to Call the Office - Integrative Medicine, Quality of Life & Concerns About Life Expectancy - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence & Discussion of OpenNotes - Questions for Our Panel of Experts

In this week's podcast, we'll learn about targeting mutant calreticulin in MPNs, or myeloproliferative neoplasms. Then, it's time to address bleeding and clotting in cancer. Results of the prospective, observational CAT-BLED study provide much needed data on the high risk of clinically relevant bleeding, and its association with all-cause mortality, among cancer patients receiving systemic therapy. Finally, we'll revisit diagnostic guidelines for familial HLH, or hemophagocytic lymphohistiocytosis. The authors present new and improved diagnostic criteria with revised clinical criteria, and guidelines on cellular and genetic diagnostic assays.Featured Articles:Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPNBleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort studyDiagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited

Send us a textLet's talk about the BCR:ABL negative MPNs! Written by Dr. Sarah Ge (Internal Medicine Resident), reviewed by Dr. Christopher Hillis @HemeHillis (Hematology) and Dr. John Neary @jddneary (General Internal Medicine). Infographic by Dr. Caitlyn Vlasschaert @DrFlashHeart (Internal Medicine Resident).Support the show

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPNs) characterized by the overproduction of red blood cells and... The post Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more appeared first on VJHemOnc.

In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including:Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the MOMENTUM trialEfficacy of pacritinib in patients with MF who have both thrombocytopenia and anemiaUpdated safety and efficacy data from the phase III MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor–naive MFImpact of spleen volume on post-allogenic hematopoietic transplant outcomes in patients with MF: utility of 3D volumetrics in splenomegalyProgression to MF in patients with essential thrombocythemia: an analysis from the prospective MOST studyJAK2V617F molecular response correlates with event-free survival in a patient population with early polycythemia veraPhase III TRANSFORM-1 study: efficacy and safety of navitoclax combined with ruxolitinib vs ruxolitinib plus placebo in patients with untreated MFPatient characteristics, treatment patterns, and health outcomes in a real-world population of patients with MF treated with fedratinib Program faculty:Brady L. Stein, MD, MHSProfessor of MedicineDepartment of Hematology/OncologyNorthwestern University Feinberg School of MedicineChicago, Illinois Resources:To download the slides associated with this podcast discussion, please visit the program page.

Myelofibrosis (MF) is a hematologic malignancy that causes progressive bone marrow fibrosis and presents with other clinical manifestations, including anemia... The post Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs appeared first on VJHemOnc.

- Overview of MPN-Related Weight Changes - Causes of Your Weight Loss or Weight Gain - Strategies for Managing Your Weight - Common Weight-Related, Eating, & Hydration Questions to Ask Your Doctor & Health Care Team - Nutrition & Hydration Concerns & Tips - Benefits of Physical Activity - How Meditation & Integrative Medicine May Help You Cope - Guidelines to Prepare for Telehealth/Telemedicine Appointments including: Technology, Prepared List of Questions, Quality-of-Life Concerns & Discussion of OpenNotes - Questions to Ask Our Panel of Experts

In the episode, we explore the family of diseases called myeloproliferative neoplasms (MPNs). Dr. Anand Patel and Dr. Olatoyosi Odenike… The post Living with Myeloproliferative Neoplasms (MPNs) first appeared on The Bloodline with LLS. The post Living with Myeloproliferative Neoplasms (MPNs) appeared first on The Bloodline with LLS.

In the episode, we explore the family of diseases called myeloproliferative neoplasms (MPNs). Dr. Anand Patel and Dr. Olatoyosi Odenike… The post Living with Myeloproliferative Neoplasms (MPNs) first appeared on The Bloodline with LLS.

- Review of the Treatments of Polycythemia Vera (PV), Essential Thrombocythemia (ET) & Myelofibrosis (MF) & Common Treatment Side Effects - Reducing Complications of Myeloproliferative Neoplasms (MPNs): What You Need to Know & Do - Key Concerns to Discuss with Your Doctor & Health Care Team, Including Treatment Side Effects & Symptoms Requiring Immediate Attention Between Appointments - Keeping a Journal of Specific Side Effects, Symptoms, Discomfort & Pain to Report to Your Doctor - Know the Warning Signs of a Potential Medical Emergency & What to Do - How Being More Assertive May Improve Your Care & Quality of Life - Questions to Ask Our Panel of Experts

- Overview of Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET) - Staging & Diagnosing - Current Standard of Care & New Treatment Approaches - Understanding Common Symptoms - Working with Your Health Care Team to Manage Your Symptoms - Strategies to Reduce Potential Complications of MPN - The Important Role of Clinical Trials - How Research Increases Your Treatment Options - Communicating with Your Health Care Team About Staging & Progression - Talking with Your Doctor About What Symptoms Should Prompt You or Your Caregiver to Call the Office - Integrative Medicine, Quality of Life & Concerns About Life Expectancy - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence & Discussion of OpenNotes - Questions to Ask Our Panel of Experts

Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY Recorded on December 19, 2023 Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, returns to discuss highlights from the 65th American Society of Hematology (ASH) Annual Meeting in December 2023, including updates on blood cancer research, treatment, and clinical trials in leukemia, lymphoma, myeloma, MDS, and MPNs. Tune in to this informative update today!

The treatment of the BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), has transformed... The post MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF appeared first on VJHemOnc.

It's been a decade since Thom Filicia, acclaimed interior designer and former co-star of “Queer Eye for the Straight Guy,” served as a bone marrow donor for his brother, Jules, who had received a diagnosis of myelofibrosis. “It was a disease I knew nothing about, I'd never even heard of it before,” Filicia told CURE®. “So that, in and of itself, was a very unusual situation, to have to navigate that. … In (Jules') situation, we needed to move very quickly. And, in his case, the most appropriate (treatment) at that time, was a bone marrow transplant, so that's what we needed to do.” Myelofibrosis, as explained by the MPN Research Foundation, is a type of chronic blood cancer that involves the formation of excessive scar tissue in the bone marrow, impairing the patient's ability to produce normal blood cells. It is part of a category of blood cancers known as myeloproliferative neoplasms, or MPNs. “Myelofibrosis is a challenge, because first of all, it's (a) very rare disease, we're talking about 25,000 people in the United States have this, maybe one in 500,000 people worldwide have this disease, so it's a very rare disease,” explained Dr. Andrew Kuykendall of the department of malignant hematology at the Moffitt Cancer Center in Tampa.  The presentation of myelofibrosis can also vary from patient to patient, as Kuykendall explained. “People can either present with just abnormal blood counts, they can present with painful abdominal pain or splenomegaly, where their spleen is enlarged or other organs can be enlarged, (or) it could be from having fevers, chills, night sweats, bone pain, a lot of symptoms that bring them to that healthcare,” Kuykendall said. “And so, it's one of those things where all those people could come with a variety of symptoms yet receive the same diagnosis. And I think that that's challenging because it doesn't necessarily present in one way. There's no kind of map. We often say, ‘The disease doesn't read the textbook,' and that's very true when it comes to myelofibrosis.” A decade after the bone marrow transplant, Filicia says his brother is in great health, and he looked back on the transplant process as a “pretty seamless” experience. “It was a good experience for both of us and a positive outcome, which is really great,” Filicia said. “I would say what it does in terms of (our relationship), we're blood brothers at a level that is very different than just being brothers because we now share the same DNA. And we've gone through this experience together, and it was a pretty impactful experience.” Filicia has now partnered with biopharma company GSK to launch the online initiative Mapping Myelofibrosis, dedicated to raising awareness about the disease with input from organizations including the MPN Research Foundation and MPN Advocacy and Education International.  The initiative's website, mappingmf.com, includes educational and informational materials as well as podcast episodes and stories from members of the myelofibrosis community of patients and loved ones, Filicia among them. “To be a resource or to be impactful in that situation, you really need information, and you need to know that you're not the only person going through it, you need to understand what other people are going through, you need to be able to connect with a doctor like Dr. Kuykendall where they can explain things to you in a way that you understand it,” Filicia said.  “And that gives you hope, and that gives you the ability to, I would imagine, move forward in a positive, thoughtful, empowered way where you feel like you're making the best decisions that you can make, for your situation, with the best guidance that you feel comfortable with.” Filicia and Kuykendall spoke with CURE®'s “Cancer Horizons” podcast about myelofibrosis, persistent misconceptions regarding bone marrow donation and the motivation behind the Mapping Myelofibrosis. For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.

The treatment and management of myeloproliferative neoplasms (MPNs) including myelofibrosis (MF) and polycythemia vera (PV) has transformed in recent years,... The post MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches appeared first on VJHemOnc.

Jess meets with Vinny Hammond, Head of Analytics and Innovation at the IRFU to hear about new technology that is being used as part of the Irish rugby team's World Cup prep. Coaches Paul O'Connell and Simon Easterby explain how it impacts the performance of the players.

Patients with BCR-ABL negative myeloproliferative neoplasms (MPNs) are at risk of progressing to accelerated-phase or blast-phase disease (MPN-AP/BP). Several mutations, including... The post Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored appeared first on VJHemOnc.

Myeloproliferative neoplasms (MPNs) represent a challenging group of diseases to treat, and patients with MPNs suffer from several symptoms which... The post The importance of addressing quality of life and improving symptom management in MPNs appeared first on VJHemOnc.

Myeloproliferative neoplasms (MPNs) represent a challenging group of diseases to treat, and patients with MPNs suffer from several symptoms which... The post The importance of addressing quality of life and improving symptom management in MPNs appeared first on VJHemOnc.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.07.12.548716v1?rss=1 Authors: Zhan, H., Zhang, H., Kafeiti, N., Lee, S., Masarik, K., Zheng, H. Abstract: Patients with JAK2V617F-positive myeloproliferative neoplasms (MPNs) and clonal hematopoiesis of indeterminate potential (CHIP) are at a significantly higher risk of cardiovascular diseases (CVDs). Endothelial cells (ECs) carrying the JAK2V617F mutation can be detected in many MPN patients. Here, we investigated the impact of endothelial JAK2V617F mutation on CVD development using both transgenic murine models and human induced pluripotent stem cell lines. Our findings revealed that JAK2V617F mutant ECs promote CVDs by impairing endothelial function and undergoing endothelial-to-mesenchymal transition (EndMT). Importantly, we found that inhibiting the endothelial thrombopoietin receptor MPL suppressed JAK2V617F-induced EndMT and prevented cardiovascular dysfunction caused by mutant ECs. These findings propose that targeting the endothelial MPL receptor could be a promising therapeutic approach to manage CVD complications in patients with JAK2V617F-positive MPNs and CHIP. Further investigations into the impact of other CHIP-associated mutations on endothelial dysfunction are needed to improve risk stratification for individuals with CHIP. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Myeloproliferative Neoplasms (MPNS) is an umbrella term that includes myelofibrosis (MF), essential thrombocythemia (ET) and polycythemia vera (PV). In this… The post Living A Full Life: Exploring Myeloproliferative Neoplasms (MPNs) first appeared on The Bloodline with LLS.

Myeloproliferative Neoplasms (MPNS) is an umbrella term that includes myelofibrosis (MF), essential thrombocythemia (ET) and polycythemia vera (PV). In this… The post Living A Full Life: Exploring Myeloproliferative Neoplasms (MPNs) appeared first on The Bloodline with LLS.

As myeloproliferative neoplasms (MPNs) carry a heavy symptom burden which can significantly impact a patient's quality of life, hear how multidisciplinary care and psycho-social support can help alleviate this burden for patients. In this episode, CANCER BUZZ speaks with Sarah Everette, LCSW and oncology social worker at Baptist Health Louisville in Kentucky about how these types of support and coordination can optimize care for patients with myeloproliferative neoplasms.  “If we get patients into physical therapy or occupational therapy early in their treatment, it helps with outcomes; it helps them [patients] not decondition so easily, especially for elderly populations. However, not only addressing their physical symptoms, but also their mental and emotional health [is important] too, because we know that we are not just caring for one aspect of the person but the whole person.” -Sarah Everette, LCSW  Sarah Everette, LCSW Oncology Social Worker Baptist Health Louisville Louisville, KY Resources: Myeloproliferative Neoplasms (cancersupportcommunity.org) The Psychosocial and Financial Aspects of Treating Myelofibrosis (accc.org)  National Comprehensive Cancer Network (NCCN) Guidelines: Myeloproliferative Neoplasms

Myeloproliferative neoplasms (MPNs) represent a heterogeneous group of diseases which remain a challenge to treat. While there have been several... The post The current role of stem cell transplantation in MPNs & how this may change with novel agents appeared first on VJHemOnc.

Myeloproliferative neoplasms (MPNs) represent a heterogeneous group of diseases which remain a challenge to treat. While there have been several... The post The current role of stem cell transplantation in MPNs & how this may change with novel agents appeared first on VJHemOnc.

As myeloproliferative neoplasms carry a significant symptom burden and oftentimes can require lifelong care coordination and close monitoring, hear how a strong multidisciplinary approach can impact shared decision-making and patient engagement. In this episode, CANCER BUZZ speaks with speaks with Andrew Kuykendall, MD, assistant member of the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Fla. and Katherine Mast, BSN, RN at Moffit Cancer Center about the impact of multidisciplinary coordination on patient care and outcomes for patients with myeloproliferative neoplasms. “When we talk about shared-decision making, I think we can talk about it in the sense of sharing that decision-making with the patient, and also sharing it with the entire [multidisciplinary] team. We like to create that engagement where we [the multidisciplinary team] are all there together—to recount what is going on, refocus what our goals of therapy are, discuss what the different options are, and then put it in the patient's hands to say ‘of these options, what do you think makes the most sense for what your goals are?'” – Andrew Kuykendall, MD “Where we can make some of the biggest impact is having people on our team who really understand what it's like to have an MPN because we see this group of patients constantly. Having one person that they can come to is wonderful, but having multiple people that are on their team that they know are there to help and answer questions can be really profoundly impactful, especially if they have a rare disease and their local hematologist/oncologist may not know as much about it.” – Katherine Mast, BSN, RN This is the third video podcast in a four-episode series on myeloproliferative neoplasms in connection with the education program “Advancing Care for Patients with Myeloproliferative Neoplasms (MPNs).” This episode is supported by Incyte. Guests: Andrew Kuykendall, MD,  Assistant Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, FL  Katherine Mast, BSN, RN  Registered Nurse Moffitt Cancer Center Tampa, FL Resources: Myeloproliferative Neoplasms (cancersupportcommunity.org) National Comprehensive Cancer Network (NCCN) Guidelines: Myeloproliferative Neoplasms  

In this week's episode we will first review a new clinical trial evidence that for patients with sickle cell anemia in resource limited settings, both low and moderate dose hydroxyurea are effective for secondary stroke prevention. Next, a research article showing how secreted mutant calreticulin functions as a “rogue cytokine” in myeloproliferative neoplasms, acting in a paracrine manner to promote growth of nearby tumor cells. Finally, we'll review new research on the pathobiology of adult and pediatric Burkitt lymphoma. With the help of whole-genome sequencing, investigators unraveled distinct subgroups, which may provide a new framework for epidemiology, diagnosis, and treatment of these lymphomas.

In this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia. The topics covered include:When to use cytoreduction therapies and which therapies to use in low-risk patientsType 1 and type 2 CALR mutations and addressing patient concerns with data from sequencing reportsExperts' thoughts on therapy options in higher-risk patientsPresenters:Prithviraj Bose, MDAssociate ProfessorDivision of Cancer MedicineDepartment of LeukemiaThe University of TexasMD Anderson Cancer CenterHouston, TexasAndrew Kuykendall, MDAssistant Professor Department of Oncologic SciencesUniversity of South FloridaAssistant MemberMalignant HematologyH. Lee Moffitt Cancer CenterTampa, Florida Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.Link to the full program, including downloadable slides and an on-demand webcast from the live event:bit.ly/3XF3cSF

As myeloproliferative neoplasms are a group of progressive blood cancers that can develop quickly into more serious hematological diseases, hear what community practices need to know about treating these patients quickly and the impact that timeliness of care can have on patient outcomes. In this episode, CANCERBUZZ speaks with Srdan Verstovsek, MD, PhD, United Energy Resources Inc. professor of Medicine and hematologist oncologist at MD Anderson Cancer Center, University of Texas, about when to begin therapeutic care for MPNs and the urgency of treatment. “We learned from experience over the last ten to twenty years that early intervention—when things are not too bad—will actually help us achieve the goals of therapy. We will have a chance to significantly decrease the size of the spleen or improve the quality of life if we do not wait for patient to be terribly sick. So, early intervention in terms of identifying the problem, objectivizing it, [and recognizing] that the symptoms are there, [indicate that we] should start the therapy now—why wait?”–Srdan Verstovsek, MD, PhD This is the second video podcast in a four-episode series on myeloproliferative neoplasms in connection with the education program “Advancing Care for Patients with Myeloproliferative Neoplasms (MPNs).” This episode is supported by Incyte. Srdan Verstovsek, MD, PhD Professor of Medicine, Department of Leukemia, Division of Cancer Medicine Hematologist Oncologist MD Anderson Cancer Center, University of Texas Houston, TX Resources: Myeloproliferative Neoplasms (cancersupportcommunity.org) MPN10: Track the Severity of your MF- or ET-related symptoms Myeloproliferative Neoplasms (MPNs): 7 questions, answered (MD Anderson Cancer Center)

Naveen Pemmaraju, MD, is the Director of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Program and an Associate Professor of Cancer Medicine at MD Anderson Cancer Center. He also serves as the Executive Director of Cancer Medicine for the MDACC Cancer Network. He is a principal investigator for several national clinical trials in MPNs, AML, and BPDCN, and he has helped develop novel targeted therapies for patients with these disorders. He led a multicenter team in a phase 1/2 clinical trial for patients with BPDCN that ultimately led to U.S. Food and Drug Administration (FDA) approval for the first targeted agent available for this rare leukemia. He has authored/co-authored over 315+ publications and has been awarded the Gerald P. Bodey Award for Excellence in Education from MD Anderson. “It is knowing the story behind the story that sets apart the ‘go-to' clinicians. They are able to make connections and discoveries about diseases and situations that other folks miss.” Tune into a conversation with Dr. Naveen Pemmaraju on clinical ‘base-building', developing a wins-'learns' mindset, and becoming innovators in our field.   Pearls of Wisdom:   1. Have a strong and fundamental base of knowledge. The best physicians aren't working the longest hours, they are working the smartest, and the reason they can do this is that they have a vast reserve of knowledge. That is the key to mastery. 2. There are no losses, only wins and learns. When you start to realize the opportunities for learning that lie in failures, that's when losses shed their disguise and become a momentous phenomenon of growth. 3. Become a leader. Be the go-to doctor for other doctors when they are faced with unsolvable, diagnostically dilemmic cases. This can only take place when you master your craft and take an effort to know the patients as people first.  

Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY Recorded on December 19, 2022 In this episode, Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, returns to provide an update on the information presented at the 64th American Society of Hematology (ASH) Annual Meeting, including leukemia, lymphoma, myeloma, MDS, and MPNs. Dr. Greenberger discusses updates in blood cancer therapies, including CAR T-cell therapy, bi-specific antibodies, and vaccine therapy, reviews the latest data on COVID-19, and addresses challenges that exist in diversity and equity in the healthcare system, including ways to overcome these barriers. Tune in today!

Myeloproliferative neoplasms (MPNs), while rare, are blood cancers that carry a significant symptom burden and can develop aggressively. Hear why community practices need to monitor symptoms carefully and about a new tool that can help assess symptoms more accurately and help care teams form treatment plans. In this episode, CANCERBUZZ speaks with Srdan Verstovsek, MD, PhD, United Energy Resources Inc. professor of Medicine and hematologist oncologist at MD Anderson Cancer Center, University of Texas and Julie Huynh-Lu, PA-C and physician assistant in the Department of Leukemia at MD Anderson Cancer Center, about MPNs and the integration of the MPN10 questionnaire into the electronic health record (EHR).  “As we recognize that quality of life is one of the major factors that we are to correct, we need to have an objective way of measuring how bad the quality of life is. We now have a full-fledged questionnaire, the MPN-10, which has ten questions that identify the ten most common problems that patients with myelofibrosis suffer from– which is very useful information for us to see what we are facing when we see the patients, [identify] the time to treat, and whether the treatment is helping.” –Srdan Verstovsek, MD, PhD This is the first video podcast in a four-episode series on MPNs in connection with the education program “Advancing Care for Patients with Myeloproliferative Neoplasms (MPNs).”  Srdan Verstovsek, MD, PhD Professor of Medicine, Department of Leukemia, Division of Cancer Medicine Hematologist Oncologist  MD Anderson Cancer Center, University of Texas Houston, TX Julie Huynh-Lu, PA-C  Physician Assistant, Department of Leukemia, Division of Cancer Medicine MD Anderson Cancer Center, University of Texas Houston, TX Resources: Myeloproliferative Neoplasms (cancersupportcommunity.org) MPN10: Track the Severity of your MF- or ET-related symptoms Myeloproliferative Neoplasms (MPNs): 7 questions, answered (MD Anderson Cancer Center)

Ruben Mesa, MD, President and Executive Director of the Atrium Health cancer service line (formerly the Executive Director of Mays Cancer Center), discusses his long career in myeloproliferative neoplasms (MPNs), the evolution of the disease, and what abstracts caught his attention at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.

Today's guest is Dr. Hugh Young Rienhoff, Jr., a San Francisco Bay Area clinical physician-scientist and entrepreneur. He serves as the CEO and a Founder of Imago BioSciences, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. In November 2022, Merck announced that it was acquiring Imago. They are using a differentiated pathway and mechanism of action to target MPNs, particularly MF, ET and PV. Imago is pioneering a novel Lysine-Specific Demethylase-1 (LSD1) inhibitor called Bomedemstat that's showing a lot of promise -- and is at the doorstep of Phase 3 trials for MF and ET. We discuss their positive clinical data, patient clinical studies and unique approach that may impede natural disease progression and offer a new weapon against MPNs.

Hear how caregivers can help patients affected by myeloproliferative neoplasms (MPNs) get the care they need by communicating the impact of MPN symptoms to Healthcare Professionals. Special guest actor, director, and health advocate LeVar Burton shares insights from Jeff and Summer as they work together to manage Summer's myelofibrosis (MF). Caregivers Nancy, Tom, and John reveal tips for taking care of their loved ones—and themselves.· Download communication workbooks for patients and caregivers at MPNPodcast.com

Myeloproliferative neoplasms (MPNs) represent a group of rare and heterogeneous diseases which remain a challenge to treat. Several advances have... The post Highlights from the 2022 Texas MPN Workshop: advances in MPN treatment appeared first on VJHemOnc.

Myeloproliferative neoplasms (MPNs) represent a group of rare and heterogeneous diseases which remain a challenge to treat. Several advances have... The post Highlights from the 2022 Texas MPN Workshop: advances in MPN treatment appeared first on VJHemOnc.

Rene Thomas Folse, JD, Ph.D. is the host for this edition which reports on the following news stories: Uber Resolves Claims for Overcharging People With Disabilities. Trial Set in Insurance Commissioner Lara "Pay-to-Play" Controversy. FBI Recovers Hospital's Ransomware Payment to North Korean Hackers. Dozens Charged in $1.2 Billion Health Care Fraud Takedown. S.F. Voters Pass New Paid Emergency Leave Effective October 1. EEOC Updates Employer Mandatory COVID Testing Guidance. 400 Truckers at AB5 Protest Shut Down Port of Oakland. CDI Adopts Advisory Rate Lower Than Requested by WCIRB. DWC Clarifies Provider Directory Requirements for MPNs. Amazon Dives into Medicine - Agrees to Acquire One Medical for $3.9B.

Myeloproliferative neoplasms (MPNs) are a class of hematological cancers characterized by the excessive production of a particular blood cell. MPNs... The post Key updates in the treatment and management of MPNs appeared first on VJHemOnc.

Myeloproliferative neoplasms (MPNs) are a class of hematological cancers characterized by the excessive production of a particular blood cell. MPNs... The post Key updates in the treatment and management of MPNs appeared first on VJHemOnc.

Listen to patients impacted by myeloproliferative neoplasms (MPNs) discuss the importance of speaking up and spelling out how their MPNs affect them. Understand why saying they were “fine” was not enough for their MPN journeys. Tune in to discover patient stories, real life experiences, and useful tips to have informed conversations with your Healthcare Professional.Get the FINE Communication Workbook at fineisnotenough.com 

The JAK-STAT pathway plays a pivotal role in the pathogenesis of myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and... The post ASH 2021: novel developments in MPNs appeared first on VJHemOnc.

The JAK-STAT pathway plays a pivotal role in the pathogenesis of myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and... The post ASH 2021: novel developments in MPNs appeared first on VJHemOnc.

Janus kinase (JAK) inhibitors are becoming an increasingly prominent class of drug in the treatment of myeloproliferative neoplasms (MPNs), in... The post Texas MPN Workshop 2021: updates on JAK inhibitors for MPNs appeared first on VJHemOnc.

Janus kinase (JAK) inhibitors are becoming an increasingly prominent class of drug in the treatment of myeloproliferative neoplasms (MPNs), in... The post Texas MPN Workshop 2021: updates on JAK inhibitors for MPNs appeared first on VJHemOnc.

Many clinical trials are currently investigating the potential benefits of interferons in the treatment of myeloproliferative neoplasms (MPNs), in particular... The post Texas MPN Workshop 2021: updates on interferons for MPNs appeared first on VJHemOnc.

Many clinical trials are currently investigating the potential benefits of interferons in the treatment of myeloproliferative neoplasms (MPNs), in particular... The post Texas MPN Workshop 2021: updates on interferons for MPNs appeared first on VJHemOnc.

The breakthrough discovery of upregulation of the JAK-STAT signaling pathway as the driving force behind myeloproliferative neoplasms (MPNs) has led... The post EHA 2021: key trial updates in myelofibrosis appeared first on VJHemOnc.